Aetiology, comorbidity and drug therapy of chronic heart failure in the real world: the EPICA substudy

被引:22
|
作者
Ceia, F
Fonseca, C
Mota, T
Morais, H
Matias, F
Costa, C
Oliveira, AG
机构
[1] Univ Nova Lisboa, Sch Med Sci, Dept Med Therapeut, Lisbon, Portugal
[2] Hosp S Francisco Xavier, Med Serv, P-1400 Lisbon, Portugal
[3] Univ Nova Lisboa, Sch Med Sci, Dept Internal Med, Lisbon, Portugal
[4] Univ Nova Lisboa, Sch Med Sci, Dept Cardiol, Lisbon, Portugal
[5] Hosp Pulido Valente, Serv Cardiol, P-1750 Lisbon, Portugal
[6] EPICA, Grp Invest, P-1050 Lisbon, Portugal
[7] Datamed Ltd, Lisbon, Portugal
[8] Datamed, P-1200 Lisbon, Portugal
关键词
heart failure; primary care; guidelines; treatment;
D O I
10.1016/j.ejheart.2004.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Chronic heart failure (CHF) is common and is frequently managed by primary care physicians (PCPs). Despite the European Society of Cardiology (ESC) Guidelines, standard treatments for CHF are frequently underutilised, particularly in primary care. Aim: To evaluate current drug therapy for CHF in adults with HF diagnosed according to ESC guidelines in the context of the EPICA study. Aetiological features and therapy relevant comorbidities were also analysed. Methods: EPICA was a community-based epidemiological study conducted in mainland Portugal. The study involved 365 primary care physicians, who evaluated 6300 primary care attendees aged over 25 years. CHIF was diagnosed by clinical and echocardiography criteria according to ESC guidelines. Results: Total of 551 cases of CHF were identified, with a mean age of 65 +/- 9 years. The estimated overall prevalence of CHF in the Portuguese population was 4.4%; 1.3% with and 1.7% without left ventricular systolic dysfunction (LVSD). There are 6,280,792 people aged > 25 years in Portugal, which extrapolates to 261,400 cases of heart failure. About 80% of patients had a history of hypertension, 39% had a history of coronary artery disease and 15% had atrial fibrillation. Only 58% of patients were on angiotensin-converting enzyme (ACE) inhibitors and 7% on beta-blockers. The type of ventricular dysfunction, age and presence of renal failure had little effect on prescription rates. Diuretics were prescribed in 78%. Thiazides were used more frequently in those with preserved systolic function and frusemide in those with left ventricular systolic dysfunction. Digoxin was prescribed more often to patients with than without left ventricular systolic dysfunction (34% vs. 17%; p = 0.02). Long-acting nitrates were prescribed to 20% and amiodarone to 8% of patients. Conclusion: The EPICA study, as in other studies in primary care in Europe, particularly the IMPROVEMENT study, suggests that greater efforts are required to improve training of primary care teams in the management of CHF. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:801 / 806
页数:6
相关论文
共 50 条
  • [1] Drug therapy in chronic heart failure
    McKenzie, DB
    Cowley, AJ
    POSTGRADUATE MEDICAL JOURNAL, 2003, 79 (937) : 634 - 642
  • [2] Drug therapy in chronic heart failure
    Jalobe, O
    POSTGRADUATE MEDICAL JOURNAL, 2004, 80 (942) : 247 - 247
  • [3] Adherence to lifestyle therapy in patient with chronic heart failure and comorbidity
    Efremova, E. V.
    Shutov, A. M.
    Makeeva, E. R.
    Serov, V. A.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1197 - 1197
  • [4] Prevalence of chronic heart failure in Southwestern Europe: the EPICA study
    Ceia, F
    Fonseca, C
    Mota, T
    Morais, H
    Matias, F
    de Sousa, A
    Oliveira, AG
    EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) : 531 - 539
  • [5] What is the relation between drug therapy and survival in real world heart failure patients?
    Yuval, R
    Levin, I
    Halon, DA
    Goldhammer, E
    Abinader, E
    Lewis, BS
    EUROPEAN HEART JOURNAL, 2002, 23 : 712 - 712
  • [6] Drug therapy - The management of chronic heart failure
    Cohn, JN
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (07): : 490 - 498
  • [7] Empaglifozin in real-world chronic heart failure
    Rocha, B.
    Cunha, G.
    Ventura Gomes, R.
    Morais, R.
    Fernandes, L.
    Campos, L.
    Araujo, I.
    Fonseca, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 177 - 178
  • [8] CHRONIC HEART FAILURE: THERAPEUTIC MANAGEMENT IN THE REAL WORLD
    Lobo Marquez, Lilia Luz
    REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA, 2011, 40 (02): : 121 - 128
  • [9] The prognostic significance of NT-proBNP in severe chronic heart failure is independent of aetiology: a substudy of the COPERNICUS trial
    Hartmann, F
    Packer, M
    Coats, AJ
    Mohacsi, P
    Tendera, M
    Amann-Zalan, I
    Baumann, M
    Katus, HA
    EUROPEAN HEART JOURNAL, 2002, 23 : 269 - 269
  • [10] Challenges in advanced chronic heart failure: drug therapy
    McDonagh, Theresa A.
    FUTURE CARDIOLOGY, 2008, 4 (05) : 517 - 525